Search hospitals

>

Connecticut

>

New Haven

Yale University

Claim this profile

New Haven, Connecticut 06510

Global Leader in Cancer

Global Leader in Breast Cancer

Conducts research for Lung Cancer

Conducts research for Solid Tumors

Conducts research for Pancreatic Cancer

1112 reported clinical trials

192 medical researchers

Photo of Yale University in New HavenPhoto of Yale University in New HavenPhoto of Yale University in New Haven

Summary

Yale University is a medical facility located in New Haven, Connecticut. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Solid Tumors, Pancreatic Cancer and other specialties. Yale University is involved with conducting 1,112 clinical trials across 1,745 conditions. There are 192 research doctors associated with this hospital, such as Nina S. Kadan-Lottick, Farzana Pashankar, Patricia M Lorusso, and Alessandro Santin.

Area of expertise

1

Cancer

Global Leader

Yale University has run 135 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage I
2

Breast Cancer

Global Leader

Yale University has run 93 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at Yale University

Breast Cancer

Skin Cancer

Lung Cancer

Multiple Myeloma

Breast cancer

Pancreatic Cancer

Ovarian Cancer

Testicular cancer

Neuroblastoma

Small Cell Lung Cancer

Image of trial facility.

Sacituzumab Tirumotecan + Pembrolizumab

for Breast Cancer

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

Recruiting

2 awards

Phase 3

3 criteria

Image of trial facility.

PF-07248144 + Fulvestrant

for Breast Cancer

The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2-negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface. Advanced cancer is a term that is often used to describe cancer that is unlikely to be cured. Metastatic cancer is the type where the cancer cells spread from one part of the body to another. This study is seeking for participants whose breast cancer has gotten worsen after receiving cyclin dependent kinase (CDK) 4/6 inhibitor-based therapy. Half of participants in this study will receive their usual study treatment, everolimus with endocrine therapy (either exemestane or fulvestrant) for HR-positive/HER2-negative advanced or metastatic breast cancer (A/mBC). The study doctor will discuss which hormone therapy is right for the participant before treatment begins. PF-07248144 is a tablet that will be taken by mouth at home every day in a 28-day cycle. Fulvestrant will be given as two injections (one injection in the buttock) at visits to the study clinic. Everolimus and exemestane are also tablets and will be taken by mouth at home every day in a 28-day cycle. The study will compare the experiences of people receiving PF-07248144 in combination with fulvestrant to those of the people who do not. This will help see if PF-07248144 in combination with fulvestrant is safe and effective.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Imlunestrant

for Early Breast Cancer

This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.

Recruiting

2 awards

Phase 3

6 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Yale University?

Where is Yale University located?

Who should I call to ask about financial aid or insurance network?

What insurance does Yale University accept?

What awards or recognition has Yale University received?